Direct cost-modeling of rheumatoid arthritis according to disease activity categories in France

Journal of Rheumatology

Volumn 38, Issue 3, 2011, Pages 439-445

  Beresniak, Ariel ^a   Gossec, Laure ^b   Goupille, Philippe ^c   Saraux, Alain ^d   Bamberger, Marion ^e   Bregman, Bruno ^e   Dupont, Danielle ^e  

^a et Institut de recherche et documentation en économie de la santé   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIVERSITÉ DE TOURS   (France)

^d UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

^e BRISTOL MYERS SQUIBB   (United States)

Author keywords

Cost of illness; Disease activity score; France; Modeling; Rheumatoid arthritis

Indexed keywords

ARTICLE; CONSULTATION; CONTROLLED STUDY; COST OF ILLNESS; DISEASE ACTIVITY; FRANCE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; JOINT RADIOGRAPHY; LABORATORY TEST; NURSING CARE; PATIENT TRANSPORT; PHYSIOTHERAPY; PRIORITY JOURNAL; REMISSION; RHEUMATOID ARTHRITIS; TECHNICAL AID;

ARTHRITIS, RHEUMATOID; COST OF ILLNESS; FRANCE; HEALTH CARE COSTS; HUMANS; MODELS, ECONOMIC; MONTE CARLO METHOD; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX;

EID: 79952380240     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.100589     Document Type: Article

References (18)

1. Lundqvist J, Kastäng F, Kobelt G, Jönsson B. The burden of rheumatoid arthritis and access to treatment: Determinants of access. Eur J Health Econ 2007;8:87-93.
2. Pugner KM, Scott DI, Holmes JW, Hieke K. The costs of rheumatoid arthritis: An international long-term view. Semin Arthritis Rheum 2000;29:305-20. (Pubitemid 30235982)
3. Rice D. Estimate the cost of illness. Am J Public Health 1967;57:424-39.
4. Leardini G, Salaffi F, Montanelli R, Gerzeli S, Canesi B. A multicenter cost-of-illness study on rheumatoid arthritis in Italy. Clin Exp Rheumatol 2002;20:505-15. (Pubitemid 34846625)
5. Ruof J, Hülsemann J, Mittendorf T, Handelmann S, von der Schulenburg JM, Zeidler H, et al. Costs of rheumatoid arthritis in Germany: A micro-costing approach based on healthcare payer's data sources. Ann Rheum Dis 2003;62:544-9.
6. Cooper N. Economic burden of rheumatoid arthritis: A systematic review. Rheumatology 2000;39:28-33. (Pubitemid 30095403)
7. Russell A, Beresniak A, Bessette L, Haraoui B, Rahman P, Thorne C, et al. Cost-effectiveness modeling of abatacept versus other biologic agents in DMARDs and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritis. Clin Rheumatol 2009;28:403-12.
8. Saraux A, Gossec L, Goupille P, Bregman B, Boccard E, Dupont D, et al. Cost-effectiveness modelling of biological treatment sequences in moderate to severe rheumatoid arthritis in France. Rheumatology 2010;49:733-40.
9. Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA, et al. Biologics for rheumatoid arthritis: An overview of Cochrane reviews. Cochrane Database Syst Rev 2009;Oct 7:CD007848.
10. Maravic M. Economic impact of rheumatoid arthritis (RA) biotherapies in France. Joint Bone Spine 2010;77:319-24.
11. Club Rhumatismes et Inflammations. Stratégies thé rapeutiques de la polyarthrite rhumatoïde en 2010. [Internet. Accessed Oct 15, 2010.] Available from: http://www.cri-net.com
12. Beresniak A, Gossec L, Goupille P, Saraux A, Bamberger M. Cost of rheumatoid arthritis model per level of disease activity in France. Value Health 2008;11:A335-62.
13. Beresniak A, Gossec L, Goupille P, Saraux A, Bamberger M, Bregman B. Cost of rheumatoid arthritis model per level of disease activity in France. Ann Rheum Dis 2008;67:608.
14. van Jaarsveld C, Jacobs J, Schrijvers A, Heurkens A, Haanen H, Bijlsma J. Direct cost of rheumatoid arthritis during the first six years: A cost-of-illness study. Br J Rheumatol 1998;37:837-47.
15. Guillemin F, Durieux S, Daures J, Lafuma A, Saraux A, Sibilia J, et al. Costs of rheumatoid arthritis in France: A multicenter study of 1109 patients managed by hospital-based rheumatologists. J Rheumatol 2004;31:1297-304. (Pubitemid 38879192)
16. Rothfuss J, Mau W, Zeidler H. Socioeconomic evaluation of rheumatoid arthritis and osteoarthritis: A literature review. Semin Arthritis Rheum 1997;26:771-9. (Pubitemid 27190964)
17. Lubeck D. The economic impact of arthritis. Arthritis Care Res 1995;8:304-10. (Pubitemid 26021966)
18. Hallert E, Husberg M, Jonsson D, Skogh T. Rheumatoid arthritis is already expensive during the first year of the disease (the Swedish TIRA Project). Rheumatology 2004;43:1-9.